Details of the Drug

General Information of Drug (ID: DMQ4HIN)

Drug Name

Cabergoline

Synonyms

Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea

Indication

Disease Entry	ICD 11	Status	REF
Hyperprolactinaemia	5A60.1	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

451.6

Topological Polar Surface Area (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability: 65% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The renal clearance of drug is 0.008 L/min [5]
Elimination: 3% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [6]
Metabolism: The drug is metabolized via the hepatic [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.00904 micromolar/kg/day [8]

Chemical Identifiers

Formula: C26H37N5O2
IUPAC Name: (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Canonical SMILES: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
InChI: InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChIKey: KORNTPPJEAJQIU-KJXAQDMKSA-N

Cross-matching ID

PubChem CID: 54746
ChEBI ID: CHEBI:3286
CAS Number: 81409-90-7
DrugBank ID: DB00248
TTD ID: D04EGX
VARIDT ID: DR00069
INTEDE ID: DR0253
ACDINA ID: D00086

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[9], [10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hyperprolactinaemia

ICD Disease Classification

5A60.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cabergoline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Memantine	DMD9WSC	Minor	Additive dopaminergic effects by the combination of Cabergoline and Memantine.	Alzheimer disease [8A20]	[39]
Promazine	DMZAL7W	Moderate	Additive CNS depression effects by the combination of Cabergoline and Promazine.	Appearance/behaviour symptom [MB23]	[40]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Cabergoline caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[41]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Cabergoline caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[41]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Cabergoline when combined with OPC-34712.	Depression [6A70-6A7Z]	[40]
Amoxapine	DMKITQE	Moderate	Antagonize the effect of Cabergoline when combined with Amoxapine.	Depression [6A70-6A7Z]	[40]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Cabergoline and Esketamine.	Depression [6A70-6A7Z]	[42]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Cabergoline caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Propiomazine	DMKY8V1	Moderate	Antagonize the effect of Cabergoline when combined with Propiomazine.	Insomnia [7A00-7A0Z]	[40]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Cabergoline when combined with ITI-007.	Insomnia [7A00-7A0Z]	[40]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Cabergoline and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[43]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Cabergoline and Lasmiditan.	Migraine [8A80]	[44]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Cabergoline and Flibanserin.	Mood disorder [6A60-6E23]	[45]
Droperidol	DM0DXA8	Moderate	Additive CNS depression effects by the combination of Cabergoline and Droperidol.	Nausea/vomiting [MD90]	[40]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Cabergoline and Prochlorperazine.	Nausea/vomiting [MD90]	[40]
Promethazine	DM6I5GR	Moderate	Antagonize the effect of Cabergoline when combined with Promethazine.	Nausea/vomiting [MD90]	[40]
Metoclopramide	DMFA5MY	Moderate	Additive CNS depression effects by the combination of Cabergoline and Metoclopramide.	Nausea/vomiting [MD90]	[40]
Thiethylperazine	DMU3IET	Moderate	Antagonize the effect of Cabergoline when combined with Thiethylperazine.	Nausea/vomiting [MD90]	[40]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Cabergoline and Dextropropoxyphene.	Pain [MG30-MG3Z]	[46]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Cabergoline when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[40]
Fluphenazine	DMIT8LX	Moderate	Antagonize the effect of Cabergoline when combined with Fluphenazine.	Psychotic disorder [6A20-6A25]	[40]
Triflupromazine	DMKFQJP	Moderate	Antagonize the effect of Cabergoline when combined with Triflupromazine.	Psychotic disorder [6A20-6A25]	[40]
Quetiapine	DM1N62C	Moderate	Additive CNS depression effects by the combination of Cabergoline and Quetiapine.	Schizophrenia [6A20]	[40]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Cabergoline when combined with Mesoridazine.	Schizophrenia [6A20]	[40]
Thioridazine	DM35M8J	Moderate	Additive CNS depression effects by the combination of Cabergoline and Thioridazine.	Schizophrenia [6A20]	[40]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Cabergoline when combined with Aripiprazole.	Schizophrenia [6A20]	[40]
Iloperidone	DM6AUFY	Moderate	Antagonize the effect of Cabergoline when combined with Iloperidone.	Schizophrenia [6A20]	[40]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Cabergoline when combined with Paliperidone.	Schizophrenia [6A20]	[40]
Loxapine	DM8AI9U	Moderate	Antagonize the effect of Cabergoline when combined with Loxapine.	Schizophrenia [6A20]	[40]
Haloperidol	DM96SE0	Moderate	Antagonize the effect of Cabergoline when combined with Haloperidol.	Schizophrenia [6A20]	[40]
Molindone	DMAH70G	Moderate	Antagonize the effect of Cabergoline when combined with Molindone.	Schizophrenia [6A20]	[40]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Cabergoline and Chlorpromazine.	Schizophrenia [6A20]	[40]
Thiothixene	DMDINC4	Moderate	Additive CNS depression effects by the combination of Cabergoline and Thiothixene.	Schizophrenia [6A20]	[40]
Clozapine	DMFC71L	Moderate	Antagonize the effect of Cabergoline when combined with Clozapine.	Schizophrenia [6A20]	[40]
Trifluoperazine	DMKBYWI	Moderate	Antagonize the effect of Cabergoline when combined with Trifluoperazine.	Schizophrenia [6A20]	[40]
Risperidone	DMN6DXL	Moderate	Antagonize the effect of Cabergoline when combined with Risperidone.	Schizophrenia [6A20]	[40]
Olanzapine	DMPFN6Y	Moderate	Antagonize the effect of Cabergoline when combined with Olanzapine.	Schizophrenia [6A20]	[40]
Amisulpride	DMSJVAM	Major	Antagonize the effect of Cabergoline when combined with Amisulpride.	Schizophrenia [6A20]	[42]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Cabergoline when combined with Asenapine.	Schizophrenia [6A20]	[40]
Pimozide	DMW83TP	Moderate	Additive CNS depression effects by the combination of Cabergoline and Pimozide.	Schizophrenia [6A20]	[40]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Cabergoline and Tizanidine.	Tonus and reflex abnormality [MB47]	[47]
Methdilazine	DMAUHQX	Moderate	Antagonize the effect of Cabergoline when combined with Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[40]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Cabergoline when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[48]
-----------


⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Leucine	E00097	6106	Antiadherent; Flavoring agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
--------------------


⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cabergoline 0.5 mg tablet	0.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 37).
2	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7.
10	Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J Neurol Sci. 2009 Mar 15;278(1-2):44-53.
11	Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35.
12	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
23	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
24	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
25	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
26	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
27	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
28	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
29	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
30	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
31	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
32	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
33	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
35	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
36	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
37	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
38	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
41	Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
42	Cerner Multum, Inc. "Australian Product Information.".
43	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
44	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
45	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
46	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
47	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
48	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.